Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
about
Acquisition of anoikis resistance in human osteosarcoma cells does not alter sensitivity to chemotherapeutic agents.The new deal: a potential role for secreted vesicles in innate immunity and tumor progressionSecreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potentialCombined elevation of microRNA-196a and microRNA-196b in sera predicts unfavorable prognosis in patients with osteosarcomas.Serum levels of microRNA-133b and microRNA-206 expression predict prognosis in patients with osteosarcomaStrategies for the targeted delivery of therapeutics for osteosarcoma.Elevated expression of CXC chemokines in pediatric osteosarcoma patientsOsteosarcoma (osteogenic sarcoma).Endothelin-1 single nucleotide polymorphisms and risk of pulmonary metastatic osteosarcomaPrognostic factors and treatment results of high-grade osteosarcoma in norway: a scope beyond the "classical" patient.Endothelin-1 promotes osteosarcoma cell invasion and survival against cisplatin-induced apoptosis.Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern.Anti-TGF-β antibody combined with dendritic cells produce antitumor effects in osteosarcoma.Down-regulation of microRNA152 is associated with the diagnosis and prognosis of patients with osteosarcomaPathological fractures in predicting clinical outcomes for patients with osteosarcoma.Expression and significance of Kruppel-like factor 6 gene in osteosarcoma.Evolving gene therapy approaches for osteosarcoma using viral vectors: reviewAlpha-CaMKII plays a critical role in determining the aggressive behavior of human osteosarcoma.Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database.p27 Is a Candidate Prognostic Biomarker and Metastatic Promoter in Osteosarcoma.In vitro generation of cytotoxic T lymphocyte response using dendritic cell immunotherapy in osteosarcoma.Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcomaSurvival trends in osteosarcoma of humerus.Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.An update on chemotherapy for osteosarcoma.MicroRNA-124 upregulation inhibits proliferation and invasion of osteosarcoma cells by targeting sphingosine kinase 1.MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1.Metastatic osteosarcoma: a challenging multidisciplinary treatment.MicroRNA-132 inhibits cell growth and metastasis in osteosarcoma cell lines possibly by targeting Sox4.MicroRNA-196a overexpression promotes cell proliferation and inhibits cell apoptosis through PTEN/Akt/FOXO1 pathway.NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcomaTIKI2 suppresses growth of osteosarcoma by targeting Wnt/β-catenin pathway.What Is New in the miRNA World Regarding Osteosarcoma and Chondrosarcoma?Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcomaPotent growth-inhibitory effect of TRAIL therapy mediated by double-regulated oncolytic adenovirus on osteosarcoma.pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.Serum miR-300 as a diagnostic and prognostic biomarker in osteosarcoma.Chemoradiotherapy in the treatment of inoperable high-grade osteosarcoma.Analysis of prognostic factors in 333 Chinese patients with high-grade osteosarcoma treated by multidisciplinary combined therapy.Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2.
P2860
Q24798873-D2869577-FC7D-426B-895F-DF233B539E79Q28084891-E2675C38-AA6E-466E-9F7B-8884F6232F7DQ30827937-9ABF5B78-4FFC-430B-ADD3-B4B1E5A50248Q33580714-4ADC6FA7-61DD-4D76-81A0-07E791F1A394Q34029191-F5D56A7E-3619-4196-85B4-C0D6FA6E966DQ34179495-B566638E-25D6-4230-8118-AF2A3EE6F418Q34380220-3A6995A7-211F-4DEB-8A8F-3CC31CF0049AQ34574274-17910914-6856-4612-8FCB-253CDC2354DDQ34998657-95591AB7-B334-4461-8A69-2202313728FBQ35138344-3220CFAD-BFAE-4E1C-ACD1-683D7D7C526BQ35242640-A63834DA-6933-4EFB-B861-94B2D56656B8Q35884951-2BD5DF40-CFD6-4916-90A4-5816765D657CQ36083713-7AA594FF-1D6E-46AC-8E4E-B86C9C44B6D3Q36095261-41A93632-6186-4205-A397-C73800A0ECF1Q36235053-825186C5-4228-426F-A7CC-47DFD72D7E60Q36285123-1497EB49-6F1B-4A19-82E9-073D2A78134CQ36692759-72B6F47D-9CB7-48BF-B5FB-8573B824A4FDQ36780837-13752A79-D206-4C79-80CF-06A94E82F513Q36946002-84572635-1637-4B6F-A794-329E4326C4F8Q37059778-8F9AD0C8-431B-43A3-ADD7-1CD2C29F4D0FQ37106823-7431DBAE-43F1-4C0D-BBA2-A198E5E7D204Q37125088-3B3912DE-73E5-4E28-AED6-A161C3808DB9Q37141239-85DA3616-FED4-4097-93BA-EA332A087DDDQ37439345-1E4E5A49-E250-484C-AD9D-06721A4AD867Q38619114-7117C418-F3F1-44D0-BD58-E60DB814CF39Q38741167-42E40A16-0970-42C5-87D6-0124852AC19EQ38768632-F958B2B6-7B9D-4A48-883A-00D4906CB98FQ38783252-E42EBDEB-7E53-48BE-8253-ABF9AACD6494Q38836625-52902E03-201B-4406-BBA0-CB12E27BAD26Q38867232-D7EBAC94-742C-4266-AD31-732243DB4379Q38921006-5ADE6146-BC43-4D23-B07A-063E249BF454Q39000894-03841963-4A10-4B02-A3E5-2EE1B662B370Q39168132-98DFE001-07B8-4DD3-8AB8-7A4B4245477DQ39246205-F08667EF-0F7C-45B2-A0C9-2075E6CF1D5AQ39392527-99C67D47-662D-448A-B48D-72C13B704633Q41533133-17DC0F03-6A59-437B-BD1F-2F4112F12673Q41764690-A9AD2DF1-0D68-4230-85B8-F7156CC4DD2DQ44582217-F5968833-3478-4AE2-AD4C-831A0FC1D5E7Q44826148-8FD8A540-C9FF-4ECE-8D2D-73B4588BE63BQ48378796-CEC1BB77-B675-4959-BB3F-2AB38CBB3FFA
P2860
Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Neoadjuvant chemotherapy for o ...... f methotrexate and ifosfamide.
@en
Neoadjuvant chemotherapy for o ...... f methotrexate and ifosfamide.
@nl
type
label
Neoadjuvant chemotherapy for o ...... f methotrexate and ifosfamide.
@en
Neoadjuvant chemotherapy for o ...... f methotrexate and ifosfamide.
@nl
prefLabel
Neoadjuvant chemotherapy for o ...... f methotrexate and ifosfamide.
@en
Neoadjuvant chemotherapy for o ...... f methotrexate and ifosfamide.
@nl
P2093
P356
P1433
P1476
Neoadjuvant chemotherapy for o ...... f methotrexate and ifosfamide.
@en
P2093
A Briccoli
M Manfrini
P Bacchini
S Galletti
P304
P356
10.1093/ANNONC/MDG286
P50
P577
2003-07-01T00:00:00Z